Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

NCT04767698 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped The funding source decided to stop funding the study.

Conditions

Multiple Sclerosis

Interventions

DRUG: Belimumab
DRUG: Short-course Ocrelizumab
DRUG: Continued Ocrelizumab

Sponsor

Johns Hopkins University

Collaborators

[object Object]